^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    D3S-002

    i
    Other names: D3S-002
    Associations

    News

    Trials
    Company:
    D3 Bio
    Drug class:
    ERK2 inhibitor, ERK1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2d
    A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations (clinicaltrials.gov)
    P1/2, N=67, Recruiting, D3 Bio (Wuxi) Co., Ltd | Active, not recruiting --> Recruiting | Trial completion date: Apr 2028 --> Aug 2028 | Trial primary completion date: Apr 2028 --> Aug 2028
    Enrollment open • Trial completion date • Trial primary completion date • First-in-human
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
    |
    BRAF V600E • EGFR mutation • KRAS G12C • BRAF V600 • EGFR L858R • EGFR T790M • KRAS G12D • ALK rearrangement • MET exon 14 mutation • EGFR L861Q • ROS1 fusion • EGFR G719X • MET mutation • EGFR S768I • RET rearrangement • KRAS G12 • KRAS G12S • KRAS Q61
    |
    D3S-002 • elisrasib (D3S-001)
    6ms
    A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations (clinicaltrials.gov)
    P1/2, N=67, Active, not recruiting, D3 Bio (Wuxi) Co., Ltd | Phase classification: P1 --> P1/2 | Trial completion date: Nov 2025 --> Apr 2028 | Trial primary completion date: Nov 2025 --> Apr 2028
    Phase classification • Trial completion date • Trial primary completion date
    |
    D3S-002 • elisrasib (D3S-001)
    12ms
    Study of D3S-002 as Monotherapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations (clinicaltrials.gov)
    P1, N=60, Active, not recruiting, D3 Bio (Wuxi) Co., Ltd | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    D3S-002
    almost3years
    Study of D3S-002 as Monotherapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations (clinicaltrials.gov)
    P1, N=60, Recruiting, D3 Bio (Wuxi) Co., Ltd | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    D3S-002
    3years
    Study of D3S-002 as Monotherapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, D3 Bio (Wuxi) Co., Ltd
    New P1 trial • Metastases
    |
    D3S-002